A major step in implementing the ETPN Translation Hub has been reached, with three European projects entering the finalisation stage of their EU Grant Agreements.
The project ENATRANS is for networking of SMEs in the nano-biomedical sector and supporting the SMEs with getting their products from the laboratory phase to the clinical applications.
The projects 'NANOFACTURING' and 'NANOPILOT' will establish pilot lines to scale-up the production of novel nanopharmaceuticals from the lab-scale to the quantities needed for clinical testing. This announcement took place during the ETPN Annual Event 2014 in San Sebastian, Spain.
The ENATRANS project (Enabling NAnomedicine TRANSlation) will ensure the global coherence of the Translation Hub and build a functioning supply chain of nanomedicine projects mainly ran by SMEs and ready to meet industrial and clinical needs. A Translational Advisory Board (TAB) will serve as the cornerstone to provide specific advice, guidance and recommendations to all nanomedicine actors dealing with translation issues and in need of assistance in specific areas of expertise.
Coordinator: ETPN Secretariat c/o VDI/VDE-IT (DE)
Consortium: Nanobiotix (FR), CEA-Leti (FR), Bioanalytik Muenster e.V. (DE), Tel-Aviv University (IL), Fondazione Don Carlo Gnocchi ONLUS (IT), and TecMinho (PT).
Duration: 3 years – Budget: € 2 Mio.
The NanoFacturing project has two principal objectives. Firstly to scale up an existing Good Manufacturing Practice (GMP) pilot line to a medium scale sustainable manufacturing process for solid core nanopharmaceuticals with a primary focus on glycan-coated gold nanoparticles. The process will also support consortium partners’ clinical programs such as IFOM’s antiviral Dengue fever NP and other EU-wide nanomedicine programs. Secondly to create a large scale process platform that would serve as the basis for GMP compliant industrial manufacture and that will be available as a model for other European companies wishing to develop their own products.
Coordinator: Midatech Biogune (ES)
Consortium: Centre for Process Innovation Limited (UK), Prochimia Surfaces SP.Z.O.O (PL), Galchimia S.A (ES), the University College Dublin and the National University of Ireland (IE), Applus S.A. LGAI Technological Center, S.A (ES), IFOM, Fondazione Istituto FIRC di Oncologia Molecolare (IT), and Ecole Polytechnique Federale de Lausanne (CH).
Duration: 4 years – Budget: € 8 Mio.
The NanoPilot project will build a pilot line for the production of polymer based nanopharmaceuticals in compliance with GMP. The size of the plant aims to be very small, with three systems to be produced at the end of the project. Continuous flow microreactors will be employed for two of the nanopharmaceuticals to be manufactured.
Coordinator: the Research Centre IK4-CIDETEC (ES)
Consortium : A Research Institute - UT2A-ADERA (FR); two Universities - National University of Ireland, Galway (IE) and Universidad de Santiago de Compostela (ES) ; two industries - Sylentis (ES) and Chemtrix (NL) ; and three SMEs - iX-Factory (DE), Mejoran (ES) and Spinverse (FI).
Duration: 4 years – Budget: € 6, 28 Mio.
Patrick Boisseau, chairman of the ETPN, added:
“We are very proud to announce such important news during the ETPN Annual Event 2014. The success of the EU calls – 18 proposals have been received for pilot lines for upscaling the manufacturing of nanopharmaceuticals - shows the adequacy of ETPN recommendations with real SMEs needs. We also look forward for the perspectives on a nano-characterisation infrastructure, another major pillar of the Translation Hub asked by European nanomedicine actors. The ETPN is excited to work hand in hand with the different coordinators for a global coherence of actions and a more efficient European value chain in nanomedicine.”
The ETPN Annual Event 2014 is taking place in San Sebastian (Spain) from October 15th to 16th, kindly co-organised by the nanoBasque Agency (SPRI) and hosted by CIC nanoGUNE, the Basque nanoscience cooperative research centre.
About ETPN ‐ www.etp‐nanomedicine.eu
The European Technology Platform Nanomedicine was established in 2005 as a joint initiative of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents, roadmaps and structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
About Midatech - http://midatechgroup.com/
Midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (GNPs) with a core focus on therapeutics for diabetes and cancer. The Company is also exploring the use of GNPs in other healthcare applications including vaccines, diagnostics and medical imaging.
About IK4 CIDETEC - www.cidetec.es
IK4-CIDETEC is a Research Institute of 125 professionals member of the Research Alliance IK4 in the Basque Country, a private and independent alliance of R&D centres. IK4 CIDETEC is specialised in generating and transferring knowledge and technology in the areas of materials, surfaces and energy. NanoPilot will be coordinated by the CIDETEC Biomaterials Unit specialised in the synthesis and characterisation of biomaterials (polymer nanoparticles, colloids, hydrogels and bioactive surfaces).
Contact / Press contact
ETPN Secretariat - ENATRANS Coordinator
Head of Secretariat
Midatech – NanoFacturing Coordinator
Justin Barry z
CEO Midatech Biogune S.L.
IK4 CIDETEC – NanoPilot Coordinator
Dr. Iraida Loinaz
Head of Biomaterials Unit
The above mentioned CSA and GMP Pilot Lines proposals have been positively evaluated by the European Commission‘s services and are under finalisation. Changes in the projects’ duration, consortium, budget or activities may thus occur within the next months.
Christoph Schmale | idw - Informationsdienst Wissenschaft
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Power and Electrical Engineering
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences